Supernus Q3 revenue rises 9% to $192.1 million; net loss of $45.1 million
Supernus reported third-quarter 2025 total revenue of $192.1 million, up 9% from a year earlier, but posted a net loss of $45.1 million, or $0.80 per diluted share, compared with net earnings of $38.5 million a year earlier. The company raised its full-year 2025 revenue guidance and narrowed its operating loss guidance, but said supplier constraints are forcing it to pause new ONAPGO patient deliveries while it rebuilds inventory.
Key points
- Total revenue was $192.1 million for the quarter, up 9%; combined revenue of the four growth products rose 52% to $149.2 million.
- Net loss was $45.1 million ($0.80 per diluted share), driven by higher SG&A that included approximately $70.0 million of Sage acquisition-related costs.
- Full-year 2025 total revenue guidance was raised to $685 million to $705 million from $670 million to $700 million; GAAP operating loss guidance is now $(65) million to $(75) million, versus $(70) million to $(80) million previously.
- Supernus is pausing delivery to patients who have not yet started ONAPGO and will provide timely updates on resolving the supply constraint.
The filing
Written by AI on Nov 8, 2026, 6:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.